The popularity of Sildenafil initially drove a surge for major pharmaceutical companies, but recent developments present a murky outlook for shareholders. Off-patent alternatives are eroding earnings, and continued legal battles add further complexity to the landscape. While certain companies might still gain from complementary products, the gen… Read More